Coupling Tumor Necrosis Factor-α with αv Integrin Ligands Improves its Antineoplastic Activity

Flavio Curnis, Anna Gasparri, Angelina Sacchi, Renato Longhi, Angelo Corti

Research output: Contribution to journalArticlepeer-review


Despite the impressive results obtained in animal models, the clinical use of tumor necrosis factor-α (TNF) as an anticancer drug is limited by severe toxicity. We have shown previously that targeted delivery of TNF to aminopeptidase N (CD13), a marker of angiogenic vessels, improved the therapeutic index of this cytokine in tumor-bearing mice. To assess whether the vascular-targeting approach could be extended to other markers of tumor blood vessels, in this work, we have fused TNF with the ACDCRGDCFCG peptide, a ligand of αv integrins by recombinant DNA technology. We have found that subnanogram doses of this conjugate are sufficient to induce antitumor effects in tumor-bearing mice when combined with melphalan, a chemotherapeutic drug. Cell adhesion assays and competitive binding experiments with anti-integrin antibodies showed that the Arg-Gly-Asp moiety interacts with cell adhesion receptors, including αvβ3 integrin, as originally postulated. In addition, ACGDRGDCFCG-mouse TNF conjugate induced cytotoxic effects in standard cytolytic assays, implying that ACGDRGDCFCG-mouse TNF conjugate can also bind TNF receptors and trigger death signals. These results indicate that coupling TNF with αv integrin ligands improves its antineoplastic activity and supports the concept that vascular targeting is a strategy potentially applicable to different endothelial markers, not limited to CD13.

Original languageEnglish
Pages (from-to)565-571
Number of pages7
JournalCancer Research
Issue number2
Publication statusPublished - Jan 15 2004

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Coupling Tumor Necrosis Factor-α with αv Integrin Ligands Improves its Antineoplastic Activity'. Together they form a unique fingerprint.

Cite this